Table 1.
Ramucirumab double-blind phase 3 RCTs.
| Study | Cancer types | Treatment exposure | Sample size | Trial registry number | Collection time |
|---|---|---|---|---|---|
| RAINBOW-Asia [27] | Advanced gastric or GEJ adenocarcinoma | RAM 8 mg/kg (days 1 and 15) + paclitaxel VS. PBO + paclitaxel | 294/146 | NCT02898077 | 2017.03.02 ∼ 2020.06.30 |
| RELAY [28] | Advanced NSCLC | RAM 10 mg/kg (IV; Q2W) + erlotinib VS. PBO + erlotinib | 224/225 | NCT02411448 | 2016.01.28 ∼ 2018.02.1 |
| REACH-2 [29] | Advanced HCC | RAM 8 mg/kg (IV; Q2W) after sorafenib + BSC VS. PBO after sorafenib + BSC | 197/95 | NCT02435433 | 2015.07.26 ∼ 2017.08.30 |
| RANGE [30] | Locally advanced or metastatic UC | RAM 10 mg/kg + docetaxel 60 or 75 mg/m2 (IV; day 1, 21-day cycle) VS. PBO + docetaxel | 263/267 | NCT02426125 | 2015.07.20 ∼ 2017.04.04 |
| RAINFALL [31] | Metastatic gastric or junctional adenocarcinoma | RAM 8 mg/kg (IV; days 1 and 8, Q21D) + cisplatin + capecitabine VS. PBO + cisplatin + capecitabine | 326/319 | NCT02314117 | 2015.01.28 ∼ 2016.09.16 |
| RAINBOW [32] | Advanced gastric or GEJ adenocarcinoma | RAM 8 mg/kg (IV; days 1 and 15) + paclitaxel VS. PBO + paclitaxel | 330/335 | NCT01170663 | 2010.12.02 ∼ 2012.09.23 |
| RAISE [33] | Metastatic colorectal carcinoma | RAM 8 mg/kg (IV; day 1, Q2W) + FOLFIRI VS. PBO + FOLFIRI | 536/536 | NCT01183780 | 2010.12.14 ∼ 2013.08.23 |
| REVEL [34] | Stage IV non-small cell lung cancer | RAM 10 mg/kg + docetaxel (IV; day 1, 21-day cycle) VS. PBO + docetaxel | 628/625 | NCT01168973 | 2010.12.03 ∼ 2013.01.24 |
| REACH [35] | Advanced hepatocellular carcinoma | RAM 8 mg/kg (IV; Q2W) after sorafenib + BSC VS. PBO after sorafenib + BSC | 283/282 | NCT01140347 | 2010.11.04 ∼ 2013.04.18 |
| REGARD [36] | Advanced gastric or GEJ adenocarcinoma | RAM 8 mg/kg (IV; Q2W) after chemotherapy + BSC VS. PBO after chemotherapy + BSC | 238/117 | NCT00917384 | 2009.10.06 ∼ 2012.01.26 |
| ROSE/TRIO-012 [37] | Metastatic breast cancer | RAM 10 mg/kg + docetaxel (IV; Q3W) VS. PBO + docetaxel | 759/385 | NCT00703326 | 2008.08 ∼ 2011.12 |
RCTs = randomized controlled trials, GEJ = gastroesophageal junction, UC = urothelial carcinoma, RAM = ramucirumab, PBO = placebo, VS. = versus, FOLFIRI = leucovorin (folinic acid), fluorouracil, and irinotecan, BSC = best supportive care, IV = intravenous, Q2W = every 2 weeks, Q3W = every 3 weeks, and Q21D = every 21 days.